Immatics Beta
| IMTX Stock | USD 10.79 0.79 6.82% |
Immatics NV fundamentals help investors to digest information that contributes to Immatics' financial success or failures. It also enables traders to predict the movement of Immatics Stock. The fundamental analysis module provides a way to measure Immatics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immatics stock.
Immatics | Beta |
Immatics Beta Analysis
Immatics' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it will be expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
More About Beta | All Equity Analysis
| 2020 | 2021 | 2022 | 2023 (projected) | Current Assets | 238.99 M | 152.21 M | 377.15 M | 308.23 M | Total Assets | 254.65 M | 174.65 M | 407.82 M | 334.22 M |
Beta | = | Covariance Variance |
Current Immatics Beta | 0.5 |
Most of Immatics' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immatics NV is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Immatics Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for Immatics is extremely important. It helps to project a fair market value of Immatics Stock properly, considering its historical fundamentals such as Beta. Since Immatics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Immatics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Immatics' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Immatics NV has a Beta of 0.5014. This is 41.7% lower than that of the Biotechnology sector and 63.93% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Immatics Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immatics' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immatics could also be used in its relative valuation, which is a method of valuing Immatics by comparing valuation metrics of similar companies.Immatics is currently under evaluation in beta category among related companies.
As returns on the market increase, Immatics returns are expected to increase less than the market. However, during the bear market, the loss on holding Immatics will be expected to be smaller as well.
Immatics Fundamentals
| Return On Equity | -0.43 | |||
| Return On Asset | -0.12 | |||
| Profit Margin | (0.85) % | |||
| Operating Margin | (0.81) % | |||
| Current Valuation | 605.21 M | |||
| Shares Outstanding | 80.4 M | |||
| Shares Owned by Insiders | 25.22 % | |||
| Shares Owned by Institutions | 48.71 % | |||
| Number of Shares Shorted | 5.88 M | |||
| Price to Earning | 44.61 X | |||
| Price to Book | 6.18 X | |||
| Price to Sales | 4.70 X | |||
| Revenue | 172.83 M | |||
| Gross Profit | 172.83 M | |||
| EBITDA | 46.34 M | |||
| Net Income | 37.51 M | |||
| Cash and Equivalents | 324.38 M | |||
| Cash per Share | 5.00 X | |||
| Total Debt | 14.56 M | |||
| Debt to Equity | 0.13 % | |||
| Current Ratio | 2.95 X | |||
| Book Value Per Share | 2.61 X | |||
| Cash Flow from Operations | 100.13 M | |||
| Short Ratio | 15.54 X | |||
| Earnings Per Share | (1.23) X | |||
| Price to Earnings To Growth | 3.00 X | |||
| Target Price | 18.29 | |||
| Number of Employees | 210 | |||
| Beta | 0.5 | |||
| Market Capitalization | 984.07 M | |||
| Total Asset | 407.82 M | |||
| Retained Earnings | (500.3 M) | |||
| Working Capital | 270.7 M | |||
| Z Score | 40.42 | |||
| Net Asset | 407.82 M |
About Immatics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immatics NV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immatics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immatics NV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor based immunotherapies for the treatment of cancer in the United States. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers and Genmab AS to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 388 people.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Immatics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Immatics' short interest history, or implied volatility extrapolated from Immatics options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Immatics NV using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Immatics Piotroski F Score and Immatics Altman Z Score analysis. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Complementary Tools for Immatics Stock analysis
When running Immatics' price analysis, check to measure Immatics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics is operating at the current time. Most of Immatics' value examination focuses on studying past and present price action to predict the probability of Immatics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics' price. Additionally, you may evaluate how the addition of Immatics to your portfolios can decrease your overall portfolio volatility.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |
Is Immatics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immatics. If investors know Immatics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immatics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.23) | Revenue Per Share 1.128 | Quarterly Revenue Growth (0.91) | Return On Assets (0.12) | Return On Equity (0.43) |
The market value of Immatics NV is measured differently than its book value, which is the value of Immatics that is recorded on the company's balance sheet. Investors also form their own opinion of Immatics' value that differs from its market value or its book value, called intrinsic value, which is Immatics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immatics' market value can be influenced by many factors that don't directly affect Immatics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immatics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immatics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immatics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.